Induction of apoptosis in glioma cell lines by TRAIL/Apo-2L

32Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.
Get full text

Abstract

TRAIL/Apo-2L, a novel cytokine, is a member of the tumor necrosis factor (TNF) family and serves as an extracellular signal triggering apoptosis. TRAIL/Apo-2L is capable of killing various transformed cells but not unstimulated primary T cells. In this study, five human glioma cells (U87, U118, U178, U563, and A172) were examined for their susceptibility to the apoptotic effects of TRAIL/Apo-2L. TRAIL/Apo-2L cDNA was isolated by RT-PCR, and recombinant TRAIL/Apo-2L protein was purified by the pMAL-c2 system (New England Biolabs, Beverly, MA). Exposure of A172 cells to bacterially expressed soluble TRAIL/Apo-2L fusion protein at a concentration of 1 μg/ml resulted in significant cell death over a 24-h period. Three experiments were performed to suggest that the TRAIL/Apo-2L killing was through the induction of apoptosis of A172 target cells. In addition, the expression of TRAIL/Apo-2L in different glioma cells was found to be variable, and TRAIL/Apo-2L-induced apoptosis was in a cell type-dependent manner. Some correlation between the susceptibility to TRAIL/Apo-2L and the expression level of one of its cognate receptors, DR4, was observed. In addition, cycloheximide worked synergistically with TRAIL/Apo-2L to induce apoptosis in glioma cells. (C) 2000 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Wu, M., Das, A., Tan, Y., Zhu, C. J., Cui, T., & Wong, M. C. (2000). Induction of apoptosis in glioma cell lines by TRAIL/Apo-2L. Journal of Neuroscience Research, 61(4), 464–470. https://doi.org/10.1002/1097-4547(20000815)61:4<464::AID-JNR14>3.0.CO;2-G

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free